で公開中です！ 詳しく見る
PACBのアイコン

Pacific Biosciences
PACB

1.73 USD
-0.23
11.73%
終値時点 更新済み 10月16日 16:00 EDT
プレマーケット
時間外取引
1.73
0.00
0%
1日
-11.73%
5日間
-22.77%
1か月
29.1%
3か月
16.11%
6か月
6.13%
年初来
-5.98%
1年
-1.7%
5年間
-92.88%
10年間
-79.65%
 

概要： Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.

従業員数： 485

ヘルスケア 医療機器

ニュース

ポジティブ
ニュートラル
ネガティブ
センチメント 3か月間
ポジティブ 24.1%
ニュートラル 55.2%
ネガティブ 20.7%
ニュートラル
Zacks Investment Research
一昨日
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors
In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.99, indicating a -2.93% shift from the previous trading day.
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors
ニュートラル
GlobeNewsWire
一昨日
PacBio to Report Third Quarter 2026 Financial Results on November 4, 2026
MENLO PARK, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2026 financial results on Wednesday, November 4, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
PacBio to Report Third Quarter 2026 Financial Results on November 4, 2026
ポジティブ
Zacks Investment Research
3 日前
PacBio Teams With TychoBio to Advance AI-Driven RNA Therapeutics
PACB partners with TychoBio to harness AI and long-read RNA sequencing for rare disease therapies, aiming to improve drug efficacy and safety through advanced data models.
PacBio Teams With TychoBio to Advance AI-Driven RNA Therapeutics
ニュートラル
Zacks Investment Research
8 日前
Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today
The latest trading day saw Pacific Biosciences of California (PACB) settling at $2.3, representing a -15.44% change from its previous close.
Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today
ニュートラル
GlobeNewsWire
10 日前
PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics
PacBio Kinnex sequencing will generate full-length transcript data to help advance TychoBio's drug discovery models PacBio Kinnex sequencing will generate full-length transcript data to help advance TychoBio's drug discovery models
PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics
ニュートラル
Zacks Investment Research
14 日前
Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts
Pacific Biosciences of California (PACB) concluded the recent trading session at $2.54, signifying a +1.2% move from its prior day's close.
Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts
ニュートラル
Schaeffers Research
15 日前
3 Biotech Stocks Put Traders Are Targeting Today
Nektar Therapeutics (NASDAQ:NKTR), Quantum-Si Inc (NASDAQ:QSI), and Pacific Biosciences of California Inc (NASDAQ:PACB) are all attracting elevated options activity today, as biotech stocks make volatile moves.
3 Biotech Stocks Put Traders Are Targeting Today
ポジティブ
Zacks Investment Research
21 日前
Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.62, marking a +2.53% move from the previous day.
Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know
ポジティブ
MarketBeat
26 日前
Pacific Biosciences Targets Clinical Growth, $40M Savings With HiFi Sequencing Push
Pacific Biosciences of California NASDAQ: PACB is maintaining its existing strategy while sharpening execution around clinical genomics, cost controls and the rollout of products designed to improve sequencing economics, Chief Executive Officer Mark Van Oene said during a Morgan Stanley discussion.
Pacific Biosciences Targets Clinical Growth, $40M Savings With HiFi Sequencing Push
ポジティブ
Zacks Investment Research
29 日前
Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today
In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.38, indicating a +2.99% shift from the previous trading day.
Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today
ニュースランキングを見る
価格チャートは Lightweight Charts™ を使用して実装されています